Notice

mylife Diabetescare is no longer part of the Ypsomed Group. Click here to visit the website.

  • English
  • German
  • 中文
Skip navigation
  • Media
  • Investors
 
Logo
Skip navigation
  • Our products
    • Product finder
    • Pen injectors
      • UnoPen
      • ServoPen
      • YpsoPen
      • YpsoFlow
      • FixPen
      • LyoTwist
      • VarioJect
    • Autoinjectors
      • YpsoLoop
      • YpsoMate
      • YpsoMate 2.25 / Pro
      • YpsoMate 5.5
      • SmartPilot for YpsoMate
      • CliniPilot for YpsoMate
      • VarioJect
    • Wearable injectors
      • YpsoDose
    • Digital Health
      • Therapy management
      • Connected devices
      • Resources
    • Innovation Hub
      • YpsoDot
      • YpsoGoECO
    Spotlight

    Good solutions come full circle

    Discover YpsoLoop
  • Our expertise
    • Track record
    • Modular platforms
      • Platform development
      • Customization process
      • Scalability
    • Manufacturing
      • Precision tooling
      • Injection molding
      • Assembly
    • Partner network
      • Final assembly services
      • Final assembly equipment
      • Packaging and labeling equipment
      • Device testing equipment
    • Services
      • Regulatory
      • Intellectual property
      • Testing & design verification
      • Quality
      • Sustainability services
      • Clear to Clinic
    Spotlight

    Streamline clinical development with Ypsomed

    Explore Clear to Clinic
  • News & insights
    • Product news
    • Company stories
    • Press releases
    • Blog
    • Events
    • Resources
    Spotlight

    Ypsomed to establish first U.S. manufacturing facility

    Read news
  • Careers
    • Working in Switzerland
      • Professionals
      • Young professionals
      • Open jobs
    • Working in Germany
      • Open jobs
  • About us
    • Management
    • Corporate strategy
    • Sustainability
    • Global presence
    • History
    • Suppliers
  • Contact
 
  • English
  • German
  • 中文
Skip navigation
  • Media
  • Investors
 
Skip navigation
  • Our products
    • Product finder
    • Pen injectors
      • UnoPen
      • ServoPen
      • YpsoPen
      • YpsoFlow
      • FixPen
      • LyoTwist
      • VarioJect
    • Autoinjectors
      • YpsoLoop
      • YpsoMate
      • YpsoMate 2.25 / Pro
      • YpsoMate 5.5
      • SmartPilot for YpsoMate
      • CliniPilot for YpsoMate
      • VarioJect
    • Wearable injectors
      • YpsoDose
    • Digital Health
      • Therapy management
      • Connected devices
      • Resources
    • Innovation Hub
      • YpsoDot
      • YpsoGoECO
    Spotlight

    Good solutions come full circle

    Discover YpsoLoop
  • Our expertise
    • Track record
    • Modular platforms
      • Platform development
      • Customization process
      • Scalability
    • Manufacturing
      • Precision tooling
      • Injection molding
      • Assembly
    • Partner network
      • Final assembly services
      • Final assembly equipment
      • Packaging and labeling equipment
      • Device testing equipment
    • Services
      • Regulatory
      • Intellectual property
      • Testing & design verification
      • Quality
      • Sustainability services
      • Clear to Clinic
    Spotlight

    Streamline clinical development with Ypsomed

    Explore Clear to Clinic
  • News & insights
    • Product news
    • Company stories
    • Press releases
    • Blog
    • Events
    • Resources
    Spotlight

    Ypsomed to establish first U.S. manufacturing facility

    Read news
  • Careers
    • Working in Switzerland
      • Professionals
      • Young professionals
      • Open jobs
    • Working in Germany
      • Open jobs
  • About us
    • Management
    • Corporate strategy
    • Sustainability
    • Global presence
    • History
    • Suppliers
  • Contact
 
Financial calendar
  • Investors
  • Financial calendar
  • Event detail

Media and Analyst Conference for the 2024/25 half-year results

13.11.2024 10:00am - 11:30am Virtual

Annual Report and Fact Sheet

  • Ypsomed Semiannual Report 2024/25 (636.1 KiB)
  • Financial key figures half-year 2024/25 (85.3 KiB)

Press release as PDF

  • Ypsomed significantly increases sales and decides to initiate the sale of Diabetes Care (108.0 KiB)
  • Video statement semiannual results 2024/25

Presentation

  • Presentation of Half-Year Results 2024/25 (7.2 MiB)
Sam Ghezelbash
Head of Investor Relations and M&A
Ypsomed Holding AG
Brunnmattstrasse 6
3401 Burgdorf
Switzerland
sam.ghezelbash@ypsomed.com
+41 76 228 51 45

Go Back

Sam Ghezelbash
Head of Investor Relations and M&A
Ypsomed Holding AG
Brunnmattstrasse 6
3401 Burgdorf
Switzerland
sam.ghezelbash@ypsomed.com
+41 76 228 51 45
TOP
Quick links
Skip navigation
  • Our products
  • Our expertise
  • About us
  • Sustainability
  • Investors
  • Media
  • Careers
  • Ypsomed Test Community
 
Legal & compliance
Skip navigation
  • Imprint
  • Terms of service
  • Data privacy and cookie policy
  • Certificates
  • Vulnerability disclosure
 
Resources & information
Skip navigation
  • Suppliers
  • Search
  • Sitemap
  • mylife Diabetes Care product resources
 
Contact

Ypsomed AG
Headquarters Burgdorf
Brunnmattstrasse 6
3401 Burgdorf
Switzerland

T +41 (0)34 424 41 11
F +41 (0)34 424 41 22
info@ypsomed.com

Subscribe to our newsletter

Follow us on
Trademarks and images

UnoPen, ServoPen, YpsoPen, YpsoFlow, FixPen, LyoTwist, VarioJect, YpsoLoop, YpsoMate, SmartPilot, CliniPilot, YpsoDose, YpsoDot, YpsoGoECO, Clear to Clinic and ClickGuide are registered trademarks of Ypsomed AG.

 

The product images shown are for illustrative purposes only. They are the property of Ypsomed AG and are used with permission.

Page last update: 25.02.2026 - 10:59am © by Ypsomed
Ypsomed Logo